PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis
G. Napoletani, S. S. Soldan, T. Kannan, S. Preston-Alp, P. Vogel, D. Maestri, L. B. Caruso, A. Kossenkov, A. Sobotka, P. M. Lieberman, I. Tempera
This study shows that PARP1 inhibition reduces EBV-driven lymphoma progression by disrupting the EBNA2/MYC axis in a mouse model.
bioRxiv · Jul 5, 2023 · PreprintCancer Biology